Aggressive breast cancers may be sensitive to drugs clogging their waste disposal

August 12, 2013

In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins.

These cancers, which lack the three major therapeutic markers for —the estrogen, progesterone and HER2 receptors—are very aggressive and difficult to treat. They mostly affect younger women and have the worst prognosis of all breast cancers.

By selectively turning genes off throughout the genomes of triple-negative in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die.

These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer .

Explore further: Paragazole excels in preclinical models of triple-negative breast cancer

Related Stories

Paragazole excels in preclinical models of triple-negative breast cancer

April 8, 2013
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast ...

Successful treatment of triple negative breast cancer by modulation of the OGF-OGFr axis

August 9, 2013
Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells ...

Drug shows promise for triple-negative breast cancer

July 3, 2012
(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by Dr. Bridgette ...

Researchers discover biological diversity in triple-negative breast cancer

February 13, 2013
Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity, according to University of North Carolina researchers.

Blocking DNA: HDAC inhibitor targets triple negative breast cancer

May 21, 2012
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research. Researchers ...

Scientists find promising new target for aggressive breast cancer

March 20, 2013
Women with triple-negative breast cancer are more likely to have high levels of the MET biomarker in their tumours, making it a good new target for cancer drugs according to research published in the British Journal of Cancer, ...

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.